Open Biosystems Launches GIPZ Lentiviral shRNAmir Library

Nov 8 2006, 7:32 AM EST

Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, today announced the availability of its Expression Arrest(TM) GIPZ lentiviral shRNAmir libraries. Targeting the entire human genome with multiple shRNAmir constructs per gene, the GIPZ lentiviral shRNAmir library builds on Open Biosystems' proven RNAi technologies that enable researchers to quickly realize the inherent value of RNAi.

The GIPZ library consists of shRNAmir constructs that have been pre-cloned into the GIPZ lentiviral vector, resulting in a powerful RNAi trigger that features increased knockdown specificity and efficiency. Open Biosystems' GIPZ shRNAmir provides researchers and scientists with expanded usability and increased delivery into a range of cell types spanning primary and non-dividing cells.

RNAi is gaining momentum and validity as a critical research tool that has the potential to dramatically impact the future of cancer diagnostics and treatment. Most recently, the National Cancer Institute (NCI) selected Open Biosystems to verify the effectiveness of shRNAmir technology in 135 specifically targeted cancer genes. This award will provide researchers with a validated set of cancer gene targeting reagents and data that can be utilized to better identify and study the specific genes involved in the development of cancer.

"Lentiviral shRNAmir is the most powerful RNAi resource available. Open Biosystems continues to arm the research community with the RNAi tools necessary to propel research efforts to the next level," said Troy Moore, chief technology officer at Open Biosystems. "It remains our mission to provide commercial and academic researchers with the proven tools and technologies to further genomic research that may lead to advanced diagnostics and treatment options for diseases such as cancer, Alzheimer's, diabetes and others."

Expression Arrest GIPZ lentiviral shRNAmir is available immediately as individual shRNAmir constructs. Gene family/pathway rearrays and the whole-genome-scale coverage will be available in January 2007. For additional information about the GIPZ library, please contact info@openbiosystems.com.

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit: www.openbiosystems.com.
© 2005-2007 Open Biosystems All Rights Reserved